CPT® Code 80374

Official Description

Stereoisomer (enantiomer) analysis, single drug class

Common Language Description

The CPT® Code 80374 refers to a laboratory test specifically designed for the analysis of stereoisomers, particularly enantiomers, within a single drug class. Stereoisomers are compounds that possess the same molecular formula and sequence of bonded atoms but differ in the three-dimensional arrangement of those atoms. This distinction is crucial in pharmacology, as the different spatial orientations can lead to significant variations in how these compounds interact within biological systems. An enantiomer is a specific type of stereoisomer that exists as a non-superimposable mirror image of another, resulting in chiral centers that impart unique properties to each form. While enantiomers may share certain biological characteristics, they often exhibit markedly different pharmacokinetic profiles, which include variations in absorption, distribution, metabolism, and excretion. These differences can also lead to distinct pharmacologic or toxicologic effects, making the analysis of enantiomers particularly important in clinical settings. Drugs can be formulated as chiral mixtures, known as racemic mixtures, or as individual enantiomers. For instance, citalopram is available in both a racemic form (R/S citalopram, marketed as Celexa) and as a pure enantiomer (S-citalopram, marketed as Lexapro). The S-enantiomer is recognized as the more effective form for inhibiting serotonin reuptake, while the R-enantiomer has a significantly reduced potency. Clinical studies have indicated that S-citalopram may provide enhanced therapeutic benefits with fewer side effects compared to its racemic counterpart. Therefore, conducting tests to measure the levels of enantiomers in blood, body tissues, or fluids can be instrumental in determining appropriate dosages, refining treatment indications, and monitoring patient responses to medication, including potential side effects and overall efficacy.

1. Indications

The procedure associated with CPT® Code 80374 is indicated for the analysis of stereoisomers (enantiomers) in a single drug class. This testing may be performed under the following circumstances:

Monitoring Drug Efficacy Testing may be necessary to evaluate the effectiveness of a prescribed medication, particularly when different enantiomers exhibit varying levels of pharmacological activity.
Assessing Side Effects The analysis can help identify which enantiomer may be contributing to adverse effects, allowing for better management of patient care.
Determining Dosage Understanding the specific enantiomer concentrations in a patient's system can assist healthcare providers in adjusting dosages to optimize therapeutic outcomes.
Narrowing Indicated Uses The test may help refine the indications for use of a drug based on the pharmacokinetic properties of its enantiomers.

2. Procedure

The procedure for CPT® Code 80374 involves several key steps to ensure accurate analysis of enantiomers within a single drug class. The following outlines the procedural steps:

Sample Collection A biological sample, which may include blood, body tissue, or body fluids, is collected from the patient. Proper collection techniques must be followed to avoid contamination and ensure the integrity of the sample.
Sample Preparation The collected sample undergoes preparation, which may involve processes such as centrifugation, filtration, or dilution, depending on the specific requirements for enantiomer analysis.
Analytical Testing The prepared sample is subjected to analytical testing methods, such as chromatography, which separates the enantiomers based on their unique chemical properties. This step is critical for accurately quantifying the levels of each enantiomer present in the sample.
Data Interpretation The results of the analysis are interpreted by qualified laboratory personnel, who assess the concentrations of the enantiomers and their potential implications for patient care.
Reporting Results Finally, the findings are compiled into a report that is communicated to the prescribing physician, providing essential information for clinical decision-making regarding the patient's treatment plan.

3. Post-Procedure

After the completion of the enantiomer analysis, the following post-procedure considerations should be noted: Patients may not require any specific post-procedure care related to the sample collection, as it is typically a routine laboratory test. However, the physician should review the results promptly to make informed decisions regarding medication adjustments or further monitoring. It is essential to communicate any significant findings to the patient, particularly if the analysis indicates a need for changes in dosage or medication type. Continuous monitoring may be recommended based on the results, especially in cases where side effects or efficacy issues are identified. Additionally, follow-up appointments may be scheduled to reassess the patient's response to treatment and ensure optimal therapeutic outcomes.

Short Descr	STEREOISOMER ANALYSIS
Medium Descr	DRUG SCREEN STEREOISOMER ANALYSIS 1 DRUG CLASS
Long Descr	Stereoisomer (enantiomer) analysis, single drug class
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1